Filo Corp., together with its subsidiaries, engages in the identification, acquisition, exploration, evaluation, and development of mineral properties in Chile and Argentina. Its flagship property ...
OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous ...